• turning early stage candidates into therapeutic commercial products

We acquire

• candidate drugs
• repurposed drugs
• medical devices
• combination drug and devices

and develop them either to proof of concept or through to registration for sale to commercial healthcare companies

Amzell Team


We have a number of products in development and are actively seeking promising new business opportunities. The existing programs are:

AMZ001 - Osteoarthritis of the knee

An easy-to-apply transdermal formulation of diclofenac relieves the pain caused by osteoarthritis of the knee. The formulation is applied locally/at the target area which improves both drug delivery and compliance. The product is precisely dosed through an airless metered dose dispenser. AMZ001 is being developed as a combination drug-device product.

AMZ001 was in-licensed from Ferring Pharmaceuticals. This innovative formulation has been designed using Amzell's proven technology for the rapid and long lasting absorption of the active constituent through the skin.

Results of the AMZ001 Phase 2 clinical trial have been presented at the OARSI World Congress 2020 and published in 'Seminars in Arthritis and Rheumatism' journal.

AMZ001 available data:

  • One Phase 2 study completed.
  • Four clinical phase 1 profiling studies completed
  • Three pre-clinical studies completed

read more

AMZ002 - Infantile epilectic disease

A highly purified sterile injectable product containing a synthetic hormone recognized as the gold standard for the treatment of catastrophic infantile epileptic disease.

AMZ002 has completed a phase 1 clinical trial. Amzell BV will initiate FDA-approved Phase 3 clinical trial of this innovative injectable treatment for infantile epileptic disease in 2021.

read more

AMZ004 - Nausea and vomiting in pregnancy

Amzell BV will conduct a phase 1 clinical study in 2021.

A discrete transdermal gel formulation of an already approved potent antiemetic drug for the treatment of severe nausea and vomiting in pregnancy (NVP) and the condition hyperemesis gravidarum (HG). This formulation offers a potential pharmacologic treatment for an unmet need with a preferred route of administration.

Amzell BV will conduct a phase 1 clinical study in 2021.

read more

How we work

We have a team of leading researchers and developers who have broad therapeutic experience. This core team directs best-in-class partners from across the world which enables us to put together a bespoke, expert team tailored to each program.